Ireland· IE-PA-EU/1/21/1539/001
Abecma 260 - 500 x 106 cells dispersion for infusion
A antineoplastic agents product containing idecabtagene vicleucel, registered in Ireland by Bristol-Myers Squibb Pharmaceuticals uc. The same ATC class is registered in 6 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Idecabtagene vicleucel is registered in 6 of 19 countries.
Countries holding a registration under ATC L01 (antineoplastic agents), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 3 of them publish a price we can compare per daily dose
Idecabtagene vicleucel · ATC L01
6 / 19 countries
- Canada
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
The record
At a glance
HPRA (Ireland)- Active substance
- Idecabtagene Vicleucel
- Manufacturer
- Bristol-Myers Squibb Pharmaceuticals uc
- Country
- Ireland (IE)
- ATC code
- L01
- ATC class
- ANTINEOPLASTIC AGENTS
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/21/1539/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Idecabtagene vicleucel in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesAbecmaCelgene Corporation
- SwitzerlandAbecma Infusionsdispersion, von 260 bis 500 × 10e6 CAR-positiven lebensfähigen T-ZellenBristol-Myers Squibb SA
- CzechiaABECMABristol-Myers Squibb Pharma EEIG, Dublin
- SpainABECMA 260-500 x 10e6 CELULAS DISPERSION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FinlandAbecmaBristol-Myers Squibb Pharma EEIG
- BelgiumAbecma 260-500 x 10*6 cellsBristol-Myers Squibb Pharma
- IcelandAbecmaBristol-Myers Squibb Pharma EEIG*
- Japanイデカブタゲン ビクルユーセルブリストル・マイヤーズ スクイブ
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Abecma
- Liechtenstein · Abecma
- Norway · Abecma
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9fafca17-68b6-4244-aeda-3e1bf7394de1 GET /v1/drugs/9fafca17-68b6-4244-aeda-3e1bf7394de1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dispersion for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L01"
],
"strength": null,
"pa_number": "EU/1/21/1539/001",
"substances": [
"Idecabtagene Vicleucel"
],
"legal_basis": "Known active substance (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "18/08/2021",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about idecabtagene vicleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.